Viking Therapeutics Presents Positive Data from VK2735 for Reducing Body Weight Effectively and Safely

Results from the VENTURE Phase II trial and a Phase I oral formulation study found that VK2735, a novel a dual GLP-1 and GIP receptor agonist, demonstrated promise in treating obesity.